Stockholm, December 19, 2023. Redwood Pharma AB (publ) announces today that the company will participate in JP Morgan’s annual Healthcare conference in San Francisco, CA, USA, on January 8-11, 2024.
Redwood Pharma will participate in JP Morgan’s annual healthcare conference, the JP Morgan Healthcare Conference. The conference is one of the largest healthcare events where global companies, fast-growing companies, innovators, financiers and investors gather.
The company’s CEO Martin Vidaeus will meet with several companies to present the medical technology treatment against dry eye, RP501, and the drug candidate RP101, as well as the company’s innovative technology platform IntelliGel. After the company received positive clinical results from the RP501 study, which shows significant therapeutic effect, safety and ease of use (most important for patients according to studies), as well as a positive outcome from the advisory meeting with the US FDA regarding RP101, we have high hopes for these meetings during the JP Morgan conference.
“During the fall’s partnering conferences in Europe, we have seen an increasing interest in our innovative treatments against dry eye. Our participation in JP Morgan’s healthcare conference in the US gives us the opportunity to make the company’s innovations visible in a broader and international context,” says Redwood Pharma’s CEO, Martin Vidaeus.
RP501 is being developed to be an effective and user-friendly product that can be given over-the-counter for the temporary relief of dry eye, a disease that affects more than 300 million people around the world. RP101 with the active substance estrogen is being developed as a treatment for post-menopausal women suffering from moderate-to-severe dry eye. Both RP501 and RP101 are based on IntelliGel – a patented and unique formulation that has the consistency of a drop of water when instilled into the eye but immediately transforms into a viscous, protective and lubricating film that remains in the eye for a long period of time.
For more information:
Martin Vidaeus, CEO Redwood Pharma AB (publ.)
Tel: +46 (0) 70 232 29 29
About Redwood Pharma
Redwood Pharma AB (publ) (Nasdaq First North Growth Market: REDW) develops next-generation treatments for dry eye. More than 300 million people suffer from dry eyes and today’s standard treatment provides only temporary relief and may need to be applied more than ten times a day. Redwood Pharma’s programs are based on IntelliGel – a patented and unique formulation of polymers and water that has the consistency of a drop of water when dropped into the eye, where it immediately forms a viscous, protective and lubricating film that remains for a long time. The company is currently pursuing two development projects: RP501 as a readily available medical device for the first line treatment of dry eye, and the drug candidate RP101 that contains estrogen for the treatment of women who suffer from dry eye after menopause. The company’s Certified Adviser is Erik Penser Bank AB, Box 7405, SE-103 91 Stockholm (+46 8 463 80 00, email@example.com). For more information, visit www.redwoodpharma.com